Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dmitry A Stetsenko

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Molecular Therapy. Nucleic Acids|January 3, 2022
Antisense oligonucleotide gapmers containing phosphoryl guanidine groups reverse MDR1-mediated multiple drug resistance of tumor cellsMaxim S Kupryushkin, Anton V Filatov, Nadezhda L Mironova, et al.
Journal of Biomedical Research|May 10, 2023
Antitumor efficacy of multi-target <i>in situ</i> vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamersAnastasia S Proskurina, Vera S Ruzanova, Genrikh S Ritter, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 8, 2020
Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potencyOlga A Patutina, Svetlana K Gaponova Miroshnichenko, Aleksandra V Sen'kova, et al.
International Journal of Molecular Sciences|November 13, 2021
New Hybrid Compounds Combining Fragments of Usnic Acid and Thioether Are Inhibitors of Human Enzymes TDP1, TDP2 and PARP1Nadezhda S Dyrkheeva, Aleksandr S Filimonov, Olga A Luzina, et al.
Anticancer Research|July 7, 2021
Experimental Comparison of the <i>In Vivo</i> Efficacy of Two Novel Anticancer TherapiesVera S Ruzanova, Anastasia S Proskurina, Genrikh S Ritter, et al.
RSC Chemical Biology|April 2, 2025
Cell-penetrating peptide-conjugated, splice-switching oligonucleotides mitigate the phenotype in <i>BTK</i>/<i>Tec</i> double deficient X-linked agammaglobulinemia modelBurcu Bestas, H Yesid Estupiñán, Qing Wang, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Molecular Therapy. Nucleic Acids|January 3, 2022
Antisense oligonucleotide gapmers containing phosphoryl guanidine groups reverse MDR1-mediated multiple drug resistance of tumor cellsMaxim S Kupryushkin, Anton V Filatov, Nadezhda L Mironova, et al.
Journal of Biomedical Research|May 10, 2023
Antitumor efficacy of multi-target <i>in situ</i> vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamersAnastasia S Proskurina, Vera S Ruzanova, Genrikh S Ritter, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 8, 2020
Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potencyOlga A Patutina, Svetlana K Gaponova Miroshnichenko, Aleksandra V Sen'kova, et al.
International Journal of Molecular Sciences|November 13, 2021
New Hybrid Compounds Combining Fragments of Usnic Acid and Thioether Are Inhibitors of Human Enzymes TDP1, TDP2 and PARP1Nadezhda S Dyrkheeva, Aleksandr S Filimonov, Olga A Luzina, et al.
Anticancer Research|July 7, 2021
Experimental Comparison of the <i>In Vivo</i> Efficacy of Two Novel Anticancer TherapiesVera S Ruzanova, Anastasia S Proskurina, Genrikh S Ritter, et al.
RSC Chemical Biology|April 2, 2025
Cell-penetrating peptide-conjugated, splice-switching oligonucleotides mitigate the phenotype in <i>BTK</i>/<i>Tec</i> double deficient X-linked agammaglobulinemia modelBurcu Bestas, H Yesid Estupiñán, Qing Wang, et al.
Pageof 5